Opaleye Management Inc.'s Form 4 filing
Grace Therapeutics, Inc.GRCE · filed Oct 13, 2026
- Accession no.
- 0001493152-26-046899
- Filed
- Oct 13, 2026, 5:45 PM ET
- Trade date
- Oct 8-12, 2026
- Filing delay
- 5 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions. Open-market purchases total $29.7K. It was filed 5 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Opaleye Management Inc.CIK 0001595855 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 8, 2026 | Common Stock, par value $0.0001 per share | PPurchaseAcquired | +2,077 | $2.02 | +$4,190.35 | 2,860,734 | Indirect | |
| Oct 9, 2026 | Common Stock, par value $0.0001 per share | PPurchaseAcquired | +5,340 | $2.04F2 | +$10,918.16 | 2,866,074 | Indirect | |
| Oct 12, 2026 | Common Stock, par value $0.0001 per share | PPurchaseAcquired | +7,215 | $2.02 | +$14,574.3 | 2,873,289 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.03 to $2.05. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price within the range.
Referenced by the price of 1 transaction in Table I.